Every 8-K that United-Guardian, Inc. (UG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow UG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UG filings page.
United-Guardian, Inc. reported higher results for the second quarter and first half of 2026. Second quarter net sales rose 10% from $2,838,225 in 2025 to $3,108,267 in 2026, while net income increased 16% from $626,826 ($0.14 per share) to $728,579 ($0.16 per share).
For the six months ended June 30, net sales grew 12% from $5,319,352 to $5,980,489, and net income increased 30% from $1,187,721 ($0.26 per share) to $1,547,481 ($0.34 per share). Management highlighted strong growth in cosmetic ingredients, with sales up 44% in the quarter and 34% in the first half, driven mainly by higher purchases from Ashland Specialty Ingredients as its inventories normalized. Pharmaceutical sales rose 1% in the quarter and 11% in the first half, with Renacidin® described as the primary driver. The company plans to continue focusing on promoting Renacidin, increasing awareness of its natural products, and expanding its medical lubricant business.
United-Guardian, Inc. announced that its Board of Directors declared a cash dividend of $0.30 per share, approved at a meeting on July 14, 2026. The dividend will be paid on August 4, 2026 to stockholders of record as of the close of business on July 28, 2026.
The company stated this marks its 31st consecutive year of paying a dividend. Management noted that the new dividend represents a 20% increase over the dividend paid this past February and reflects the Board’s assessment of financial performance, anticipated expenses, and ongoing initiatives, as well as confidence in the company’s direction.
United-Guardian, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected seven directors, including Ken Globus and Donna Vigilante, to serve until the next annual meeting or until successors are elected and qualified.
Stockholders approved holding future advisory votes on executive compensation every year, with 2,576,591 votes for that frequency. They also approved executive compensation on a non-binding advisory basis, with 2,562,179 votes in favor. In addition, shareholders ratified the appointment of Grassi & Co., CPAs P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 3,566,216 votes for ratification.
United-Guardian, Inc. reported significantly improved first quarter 2026 results, with net sales rising to $2,872,222 from $2,481,127 in 2025 and net income increasing to $818,902, or $0.18 per share, from $560,895, or $0.12 per share.
Management attributed the performance mainly to stronger sales of pharmaceuticals and cosmetic ingredients. Pharmaceutical sales rose 24%, led by higher demand for Renacidin, while cosmetic ingredient sales grew 21%, supported by a 45% increase in purchases from Ashland Specialty Ingredients as it normalized inventory levels.
Other income also boosted results, including $303,133 of settlement income related to a contract manufacturer shutdown for Renacidin, alongside investment income and gains on marketable securities. The company highlighted new distribution agreements, expanded “natural” product lines, and broader Renacidin outreach as reasons to be optimistic about further sales growth in 2026.
United-Guardian, Inc. reported weaker full-year 2025 results, with net sales falling 13% to $10,545,468 from $12,181,971 in 2024. Net income declined to $2,105,738, or $0.46 per share, compared with $3,250,875, or $0.71 per share, a year earlier.
Management attributed the decline mainly to lower cosmetic ingredient sales, driven by excess inventory at its largest distributor Ashland Specialty Ingredients, softer global demand, stronger local competition in China, and tariffs. Offsetting this, pharmaceutical sales grew 15% and medical lubricants 4%, helped by higher demand in China and U.S. drug wholesalers, while Renacidin® gained access to additional drug formularies through recent approvals from two major pharmacy benefit managers.
United-Guardian, Inc. filed a current report to furnish information under Regulation FD. The company stated that on January 29, 2026 it issued a press release, which is attached to the report as Exhibit 99.1 and incorporated by reference for public disclosure.
United-Guardian, Inc. filed a current report to note that it released an earnings-related press release. Under the item covering results of operations and financial condition, the company states that on November 6, 2025 it issued a press release, which is attached as Exhibit 99.1 and incorporated by reference. The filing itself does not include the detailed financial results, directing readers instead to the attached exhibit for full information.
United-Guardian, Inc. filed a current report describing the release of a press announcement about its results of operations and financial condition. The company stated that it issued this press release on August 8, 2025, and attached it as an exhibit for investors and the public to review.